CSBR Stock Forecast: Champions Oncology, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 27 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Champions Oncology, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (78): The share price has been relatively steady.
Momentum (18): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
CSBR stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on CSBR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 Mar 2025 | Craig-Hallum | Maintains | Buy | $8.00 → $12 |
| 12 Dec 2024 | Craig-Hallum | Maintains | Buy | — |
| 12 Sept 2024 | Craig-Hallum | Upgrade | Buy | — |
| 13 Mar 2024 | Craig-Hallum | Downgrade | Hold | — |
| 22 Sept 2023 | Roth MKM | Maintains | Buy | — |
| 15 Mar 2021 | Roth Capital | Maintains | Buy | — |
| 18 Nov 2019 | Benchmark | Initiates | Speculative Buy | — |
| 20 Sept 2019 | Roth Capital | Initiates | Buy | — |
| 24 July 2019 | Janney Capital | Downgrade | Neutral | — |
| 24 July 2019 | Janney Montgomery Scott | Downgrade | Neutral | — |
| 17 July 2018 | Craig-Hallum | Initiates | Buy | — |
| 15 May 2018 | Dawson James | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
CSBR appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
CSBR vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Champions Oncology, Inc. returned −34.7% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
CSBR analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 1.0×
- Price / book
- 15.9×
- EV / EBITDA
- 170.2×
Cheaper than 65% of US stocks
Cheaper than 4% of US stocks
Cheaper than 2% of US stocks
- Revenue growth (YoY)
- 8.8%
- Earnings growth (YoY)
- —
- Gross margin
- 50.8%
- Operating margin
- −1.5%
- Net margin
- −1.9%
Higher than 51% of US stocks
Higher than 63% of US stocks
Higher than 33% of US stocks
Higher than 28% of US stocks
- Return on equity
- −28.4%
- Return on assets
- −1.8%
- Dividend yield
- —
Higher than 29% of US stocks
Higher than 38% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Champions Oncology, Inc. has a market value of $61.2M and an enterprise value of $68.4M.
Revenue in the twelve months to 30 Apr 2026: $59.4M. The latest quarter grew 12.0% year on year.
Net income over the same four quarters: −$1.1M, a −1.9% net margin.
Free cash flow in the twelve months to 30 Apr 2026: −$5.0M.
forward P/E: 44.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Champions Oncology, Inc. employs 214 people — $278K of revenue per employee.
Data provided by Twelve Data
CSBR and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at CSBR’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Champions Oncology, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about CSBR
How does Ticker Nerd's model rank CSBR?
As at 21 Nov 2026, Champions Oncology, Inc. ranks 27 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (78 of 100).
What is the CSBR stock forecast for 2030?
No analyst covering Champions Oncology, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CSBR are extrapolating price history, which says nothing about the business.
How has CSBR stock performed over the past year?
Champions Oncology, Inc. returned -34.7% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Champions Oncology, Inc. do?
Champions Oncology, Inc. is a biotechnology research services company focused on oncology drug development. Champions Oncology provides preclinical and clinical specialty testing, translational research, and data-driven software solutions that help pharmaceutical and biotechnology companies evaluate cancer therapies.
About Champions Oncology, Inc.
Champions Oncology, Inc. is a biotechnology research services company focused on oncology drug development. Champions Oncology provides preclinical and clinical specialty testing, translational research, and data-driven software solutions that help pharmaceutical and biotechnology companies evaluate cancer therapies. Its core offerings include proprietary tumor models, in vivo and ex vivo research platforms, biomarker analysis, and the TumorGraft technology platform, which supports more personalized approaches to oncology research. The company also offers Lumin Bioinformatics, a software platform that combines research and clinical data for computational cancer analysis and decision-making support. Champions Oncology serves drug developers, research organizations, and medical professionals through technology-enabled services centered on improving the understanding and development of cancer treatments. Headquartered in Hackensack, New Jersey, Champions Oncology operates as a specialized provider within the broader oncology contract research and life sciences tools market.
CEO Mr. Robert Brainin · 214 employees · United States · https://www.championsoncology.com